Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.

Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML.

J Clin Invest. 2011 Jan;121(1):308-17. doi: 10.1172/JCI40594. Epub 2010 Dec 22.

2.

CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients.

Ragab D, Laird M, Duffy D, Casrouge A, Mamdouh R, Abass A, Shenawy DE, Shebl AM, Elkashef WF, Zalata KR, Kamal M, Esmat G, Bonnard P, Fontanet A, Rafik M, Albert ML.

Cytokine. 2013 Aug;63(2):105-12. doi: 10.1016/j.cyto.2013.04.016. Epub 2013 May 7. Erratum in: Cytokine. 2014 Jan;65(1):119-20.

PMID:
23664274
3.

Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.

Meissner EG, Decalf J, Casrouge A, Masur H, Kottilil S, Albert ML, Duffy D.

PLoS One. 2015 Jul 16;10(7):e0133236. doi: 10.1371/journal.pone.0133236. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0139818.

4.

Chemokine antagonism in chronic hepatitis C virus infection.

Charles ED, Dustin LB.

J Clin Invest. 2011 Jan;121(1):25-7. doi: 10.1172/JCI45610. Epub 2010 Dec 22.

5.

Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection.

Riva A, Laird M, Casrouge A, Ambrozaitis A, Williams R, Naoumov NV, Albert ML, Chokshi S.

Hepatology. 2014 Aug;60(2):487-96. doi: 10.1002/hep.27139. Epub 2014 May 19.

PMID:
24668726
6.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

7.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

8.
9.

Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.

Kondo Y, Ueno Y, Ninomiya M, Tamai K, Tanaka Y, Inoue J, Kakazu E, Kobayashi K, Kimura O, Miura M, Yamamoto T, Kobayashi T, Igarashi T, Shimosegawa T.

J Gastroenterol. 2012 Dec;47(12):1323-35. doi: 10.1007/s00535-012-0596-x. Epub 2012 May 16.

PMID:
22588246
10.

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.

Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups.

Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509.

PMID:
20186843
11.

Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C.

Gut. 2006 Mar;55(3):374-9. Epub 2005 Sep 8.

12.

Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.

Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY, Chien RN.

Aliment Pharmacol Ther. 2013 Jan;37(1):81-90. doi: 10.1111/apt.12112. Epub 2012 Nov 5.

13.

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.

El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, Hotta H.

PLoS One. 2012;7(2):e30513. doi: 10.1371/journal.pone.0030513. Epub 2012 Feb 2.

14.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
15.

Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.

Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín-Carbonero L, Rodríguez-Nóvoa S, Santos I, López-Cortes LF, Merino D, Rivero A, Soriano V.

Antivir Ther. 2008;13(3):429-37.

PMID:
18572756
16.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
17.

[Chronic hepatitis C virus infection: clinical picture and treatment possibilities].

Annicchiarico BE, Siciliano M, Gasbarrini A.

G Ital Nefrol. 2012 Jan-Feb;29 Suppl 54:S103-8. Italian.

PMID:
22388839
18.
19.

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.

Zhang Y, Liu Y, Zhao Y, Shi L, Ma L, Yan H, Wu H, Wei L, Dong T, Chen X.

Liver Int. 2012 Jan;32(1):102-9. doi: 10.1111/j.1478-3231.2011.02652.x. Epub 2011 Sep 26.

PMID:
22098382
20.

Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.

Covini G, Carcamo WC, Bredi E, von Mühlen CA, Colombo M, Chan EK.

Antivir Ther. 2012;17(5):805-11. doi: 10.3851/IMP1993. Epub 2011 Dec 1.

PMID:
22293655
Items per page

Supplemental Content

Write to the Help Desk